Press release
Metastatic Prostate Cancer Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, | Key Companies - Foresee Pharma (FP-001), Myovant B
"Metastatic Prostate Cancer Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Prostate Cancer Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Metastatic Prostate Cancer Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Metastatic Prostate Cancer Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Prostate Cancer treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Prostate Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Metastatic Prostate Cancer Therapeutics Domain:
https://www.delveinsight.com/report-store/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Intradermal
• Intra-tumoral
• Oral
• Parenteral
• Subcutaneous
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Prostate Cancer Therapeutics Analysis
There are approx. 90+ key companies which are developing the therapies for Metastatic Prostate Cancer. Currently, Foresee Pharmaceuticals and Myovant Biosciences are leading the therapeutics market with their Metastatic Prostate Cancer drug candidates in the most advanced stages of clinical development.
The Leading Players in the Metastatic Prostate Cancer Therapeutics Market Include:
AB Science, Abbvie, Advanced Accelerator Applications (A Novartis Company), Advaxis, Amgen, , Antigen Express, Aptevo Therapeutics, Arcus Biosciences, Arvinas Inc., Astellas Pharma Inc, Astellas Pharmaceuticals, AstraZeneca plc, Bavarian Nordic, Bayer, Beigene, BioNTech SE, Boehringer Ingelheim, Bristol Myers Squibb, Cancer Targeted Technology, Celgene, CellCentric, Cleveland BioLabs, Constellation Pharmaceuticals, Corcept Therapeutics, DexTech Medical, Effector Therapeutics, Eli Lilly and Company, Epizyme Inc., ESSA Pharma, Five Eleven Pharma, Foresee Pharmaceuticals, Fortis Therapeutics, Genentech, Genzada Pharmaceuticals, Gilead, Harpoon Therapeutics, Hinova Pharmaceuticals USA, Inc., Immunomedics, Inhibitor Therapeutics, Inc., Innocrin Pharmaceutical, Inovio Pharmaceuticals, Janssen Research & Development, LLC, Jiangsu HengRui Medicine Co., Ltd., Kangpu Biopharmaceuticals, Karyopharm Therapeutics, Laekna Therapeutics Shanghai Co. Ltd., Madison Vaccines, Inc, MedImmune, Medivation, Merck Sharp & Dohme Corp., Minneamrita Therapeutics, Modra Pharmaceuticals, Myovant Biosciences, Nektar Therapeutics, Nerviano Medical Sciences, NewLink Genetics, Novartis, Oncology Venture, OncoMax, OPKO Renal/Vifor Fresenius, ORIC Pharmaceuticals, Orion Corporation, Orion Pharma, Pfizer Inc., Poseida Therapeutics, Progenics Pharmaceuticals, Inc., Regeneron Pharmaceuticals/Sanofi, Roche, SeleXel, Sotio, Suzhou Kintor Pharmaceutical, Taiho Pharmaceutical, Telix Pharmaceuticals, Tesaro, Tmunity Therapeutics, Tracon, Trovagene, Ultimovacs ASA, Vaccitech, ValiRx, VasGene Therapeutics, Veru Inc., WntResearch, Zenith Epigenetics, and others.
Metastatic Prostate Cancer Emerging and Marketed Drugs Covered in the Report Include
• FP-001: Foresee Pharmaceuticals
• Relugolix: Myovant Biosciences
• Atezolizumab: Genentech
• Darolutamide: Bayer
• DCVAC/PCa: Sotio
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Metastatic Prostate Cancer Current Treatment Patterns
4. Metastatic Prostate Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Prostate Cancer Late-Stage Products (Phase-III)
7. Metastatic Prostate Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Prostate Cancer Discontinued Products
13. Metastatic Prostate Cancer Product Profiles
14. Metastatic Prostate Cancer Key Companies
15. Metastatic Prostate Cancer Key Products
16. Dormant and Discontinued Products
17. Metastatic Prostate Cancer Unmet Needs
18. Metastatic Prostate Cancer Future Perspectives
19. Metastatic Prostate Cancer Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/metastatic-prostate-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Prostate Cancer Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Treatment Outlook, | Key Companies - Foresee Pharma (FP-001), Myovant B here
News-ID: 3013594 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
